{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:55:33Z","timestamp":1773071733527,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.neuropharm.2012.02.021","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T11:47:36Z","timestamp":1331293656000},"page":"2499-2506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment"],"prefix":"10.1016","volume":"62","author":[{"given":"Marisa","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan L.","family":"Du Preez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian H.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.02.021_bib1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0278-5846(02)00220-8","article-title":"The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. the possible role of oxidant\/antioxidant imbalance","volume":"26","author":"Akyol","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0014-827X(03)00140-X","article-title":"Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals","volume":"58","author":"Allegri","year":"2003","journal-title":"Il Farmaco"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1570-0232(02)00572-X","article-title":"Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography\u2013electrospray ionization tandem mass spectrometry","volume":"780","author":"Amirkhani","year":"2002","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib4","doi-asserted-by":"crossref","first-page":"9985","DOI":"10.1073\/pnas.93.18.9985","article-title":"Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry","volume":"93","author":"Andreasen","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1192\/pb.21.4.224","article-title":"Chlorpromazine equivalents: a concensus of opinion for both clinical and research applications","volume":"21","author":"Atkins","year":"1997","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/schbul\/sbm134","article-title":"Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia","volume":"34","author":"Ascher-Svanum","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881108089583","article-title":"Kynurenine pathway in psychosis: evidence of increased tryptophan degradation","volume":"23","author":"Barry","year":"2009","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0022-3565(25)23831-9","article-title":"Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response","volume":"271","author":"Bakshi","year":"1994","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for Schizophrenia \u2013 a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2005.05.019","article-title":"The many faces of nitric oxide in schizophrenia. A review","volume":"78","author":"Bernstein","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.freeradbiomed.2009.07.034","article-title":"Oxidative stress upregulates the NMDA receptor on cerebrovascular endothelium","volume":"47","author":"Betzen","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/02713680490904377","article-title":"Clozapine directly relaxes bovine retinal arteries","volume":"30","author":"Boussery","year":"2005","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2006.03.029","article-title":"Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus","volume":"85","author":"Byne","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","article-title":"Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence","volume":"41","author":"Carlsson","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jchromb.2009.01.015","article-title":"Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC \u2013 tandem mass spectrometry","volume":"877","author":"de Jong","year":"2009","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00002826-200101000-00008","article-title":"A\u00a0revised excitotoxic hypothesis of schizophrenia: therapeutic implications","volume":"24","author":"Deutsch","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","article-title":"d-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia","volume":"56","author":"Evins","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.neubiorev.2008.03.003","article-title":"Behavioural and neurochemical effects of post-weaning social isolation in rodents \u2013 relevance to developmental neuropsychiatric disorders","volume":"32","author":"Fone","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1461145709990770","article-title":"Autoantibodies from schizophrenia patients induce cerebral cox-1\/iNOS mRNA expression with NO\/PGE2\/MMP-3 production","volume":"13","author":"Ganzinelli","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpsyc.57.1.65","article-title":"Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia","volume":"57","author":"Glantz","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A\u00a0placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib22","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.1523\/JNEUROSCI.4101-07.2007","article-title":"Characterization of the kynurenine pathway in human neurons","volume":"27","author":"Guillemin","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"Pt. 2","key":"10.1016\/j.neuropharm.2012.02.021_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj3260351","article-title":"Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types","volume":"326","author":"Heyes","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02245458","article-title":"Inhibition of neuronal nitric oxide synthase by antipsychotic drugs","volume":"114","author":"Hu","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib25","article-title":"Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation","author":"Hu","year":"2011","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(94)90069-8","article-title":"A\u00a0multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. comparisons with healthy control subjects and neuroleptic-treated\/unmedicated pairs analyses","volume":"52","author":"Issa","year":"1994","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib27","first-page":"4","article-title":"Glutamatergic theories of schizophrenia","volume":"47","author":"Javitt","year":"2010","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3371\/CSRP.4.3.6","article-title":"Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models","volume":"4","author":"Kantrowitz","year":"2010","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the first 24 hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib30","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatrica. Scand."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2009.05.063","article-title":"Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation","volume":"1283","author":"Magliaro","year":"2009","journal-title":"Brain Res."},{"issue":"Suppl.","key":"10.1016\/j.neuropharm.2012.02.021_bib34","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pneurobio.2009.10.018","article-title":"Epidemiology-driven neurodevelopmental animal models of schizophrenia","volume":"90","author":"Meyer","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2005.12.056","article-title":"Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder","volume":"1073\u20131074","author":"Miller","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.neuint.2008.01.013","article-title":"Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder","volume":"52","author":"Miller","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.euroneuro.2010.09.006","article-title":"Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration","volume":"21","author":"M\u00f6ller","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib39","unstructured":"M\u00f6ller, M., Du Preez, J. L., & Harvey, B. H., submitted for publication. Development and validation of a single analytical method for the determination of tryptophan, and its kynurenine metabolites in rat plasma. J. Chromatogr. B."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jad.2006.07.013","article-title":"Kynurenine pathway in major depression: evidence of impaired neuroprotection","volume":"98","author":"Myint","year":"2007","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jad.2006.12.008","article-title":"Tryptophan breakdown pathway in bipolar mania","volume":"102","author":"Myint","year":"2007","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib42","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbi.2011.05.005","article-title":"Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-na\u00efve and medication-free schizophrenic patients","volume":"25","author":"Myint","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008877-200305000-00010","article-title":"Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine","volume":"14","author":"Nel","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1017\/S1461145707008401","article-title":"Oxidative stress in psychiatric disorders: evidence base and therapeutic implications","volume":"11","author":"Ng","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib46","first-page":"231","article-title":"Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders","volume":"48","author":"Ravikumar","year":"2000","journal-title":"Neurol. India"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","article-title":"Increased cortical kynurenate content in schizophrenia","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2003.10.006","article-title":"The kynurenine pathway of tryptophan degradation as a drug target","volume":"4","author":"Schwarcz","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.npp.1300255","article-title":"Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid","volume":"28","author":"Schwieler","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","article-title":"Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area","volume":"83","author":"Schwieler","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0301-0082(00)00032-0","article-title":"Kynurenines in the CNS: from endogenous obscurity to therapeutic importance","volume":"64","author":"Stone","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib54","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1515\/CCLM.2003.129","article-title":"Tryptophan metabolites and brain disorders","volume":"41","author":"Stone","year":"2003","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","article-title":"Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice","volume":"33","author":"Sugino","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.bp.106.033670","article-title":"Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia","volume":"191","author":"Theberge","year":"2007","journal-title":"Brit. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-9964(97)88530-1","article-title":"Increased CSF and brain quinolinic acid in schizophrenia and bipolar disorder","volume":"29","author":"Torrey","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib58","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuroscience.2009.10.039","article-title":"The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats","volume":"165","author":"Toua","year":"2010","journal-title":"Neurosci"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib59","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.bbi.2010.04.015","article-title":"Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2,3-dioxygenase","volume":"24","author":"Wang","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002130100800","article-title":"Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review","volume":"156","author":"Weiss","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000054885","article-title":"Neurodevelopmental schizophrenia: obstetric complications, birth weight, premorbid social withdrawal and learning disabilities","volume":"43","author":"Willinger","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.157.1.16","article-title":"Meta-analysis of regional brain volumes in schizophrenia","volume":"157","author":"Wright","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.02.021_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/7854_2010_62","article-title":"Animal models of schizophrenia","volume":"4","author":"Young","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib64","first-page":"2533","article-title":"Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics","volume":"10","author":"Zhang","year":"1999","journal-title":"Neuropharm. Neurotoxicol."},{"key":"10.1016\/j.neuropharm.2012.02.021_bib65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.euroneuro.2009.10.002","article-title":"The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues","volume":"20","author":"Zhang","year":"2010","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:53:52Z","timestamp":1762214032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0028390812000822"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.02.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}